Search

Your search keyword '"eplerenone"' showing total 30 results
Start Over Descriptor "eplerenone" Publication Type Magazines
30 results on '"eplerenone"'

1. Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician

Author

Bakris, George

Subjects
Empagliflozin, Continuing medical education, Sodium zirconium cyclosilicate, Eplerenone, Hypoglycemic agents, Kidney diseases -- Development and progression -- Care and treatment, Target marketing, Patiromer, Evidence-based medicine, Endothelin, Family medicine, Type 2 diabetes -- Development and progression -- Care and treatment, Diabetes therapy, Primary care nursing, Dulaglutide, Semaglutide, Health
Abstract

CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES At the end of the activity, participants will be able to: * Identify the risks of kidney disease and their consequences in patients with T2DM. [...]

Published
2020

2. Serous Business: CSR can be treated a number of different ways--but should it be?

Author

Haynie, Jay M., Shechtman, Diana, and Taher, Rashid

Subjects
Retinal diseases -- Case studies -- Care and treatment, Ophthalmological therapeutics -- Methods, Pantoprazole, Corporate social responsibility, Tomography, Eplerenone, Epithelium, Verteporfin, Health
Abstract

Central serous retinopathy (CSR) is thought to be an idiopathic disorder typically found in the macula, characterized by a neurosensory detachment from the retinal pigment epithelium (RPE) and a localized [...]

Published
2019

4. Pfizer, Mylan agree to divestitures for Upjohn deal, FTC says

Subjects
United States. Federal Trade Commission, Pfizer Inc. -- Mergers, acquisitions and divestments, Eplerenone, Company acquisition/merger, Business, News, opinion and commentary
Abstract

Pfizer (PFE) and Mylan (MYL) have agreed to divest assets and abide by other conditions to settle Federal Trade Commission charges that the proposed combination of Upjohn and Mylan will [...]

Published
2020

5. Investigators from Pharos University Alexandria Target Aldosterone Receptor Antagonists (Simultaneous Micro-determination of Eplerenone and Torsemide In Their Combined Tablets Using Hptlc-dual Wavelength Spectrodensitometric and ...)

Subjects
Physical fitness, Torsemide, Eplerenone, Aldosterone, Glucocorticoids, Cardiac patients, Health
Abstract

2020 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Drugs and Therapies - Aldosterone Receptor Antagonists. [...]

Published
2020

6. Researchers' Work from University Medical Center Utrecht Focuses on Steroid Receptors (A combined CaMKII inhibition and mineralocorticoid receptor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice)

Subjects
Physical fitness, Calcium binding proteins, Medical centers, Eplerenone, Health
Abstract

2020 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Proteins - Steroid Receptors have been presented. According to [...]

Published
2020

7. Central amygdala mineralocorticoid receptors modulate alcohol self-administration

Subjects
Physical fitness, Neurosciences, Drinking (Alcoholic beverages), Eplerenone, Corticosterone, Obesity, Aldosterone, Brain research, Glucocorticoids, Editors, Health
Abstract

2020 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2020

8. Choroidal lymphoma or something else?

Author

Arias, Diego, Lally, Sara, and Shields, Carol

Subjects
Eye tumors -- Case studies -- Diagnosis -- Care and treatment, Lymphomas -- Case studies -- Diagnosis -- Care and treatment, Monoclonal antibodies, Chronic obstructive lung disease, Lung diseases, Operating systems (Software), Eplerenone, Tumors, Psoriasis, Respiratory tract diseases, Women, Diseases, Physicians, Antibodies, Corticosteroid drugs, Non-Hodgkin's lymphomas, Health
Abstract

Byline: Diego. Arias, Sara. Lally, Carol. Shields Case A 54-year-old asymptomatic Caucasian woman with a history of psoriasis and chronic obstructive pulmonary disease (COPD) under treatment with topical and oral [...]

Published
2020

9. Commentary: Our understanding of central serous chorioretinopathy--coming a full circle?

Author

Mohan, Ashwin, Soman, Manoj, and Nair, R.

Subjects
Retinal diseases -- Diagnosis -- Care and treatment, Epithelium, Corticosteroid drugs, Eplerenone, Health
Abstract

Byline: Ashwin. Mohan, Manoj. Soman, R. Nair Central serous chorioretinopathy was first described by Von Graefe in 1866 as 'Ueber centrale recidivirende retinitis'.[1] The usage of the term 'retinitis' suggests [...]

Published
2020

10. Study Results from Royal Veterinary College Update Understanding of Chronic Kidney Disease (Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease)

Subjects
Physical fitness, Eplerenone, Aldosterone, Glucocorticoids, Chronic kidney failure, Oxidative stress, Kidney diseases, Editors, Diseases, Health
Abstract

2020 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Kidney Diseases and Conditions - Chronic Kidney [...]

Published
2020

11. Patent Issued for Renal Selective Inhibition Of Cytochrome P450 3A5 (USPTO 10,538,769)

Subjects
Lercanidipine -- Intellectual property, Bucindolol, Physical fitness, Antihypertensive agents, Angiotensin II receptor blockers, Hypertension, Torsemide -- Intellectual property, Angiotensin II -- Intellectual property, Eplerenone, Angiotensin converting enzyme inhibitors, Aliskiren, Valsartan, Phenoxybenzamine, Anopheles, Oxprenolol, Trandolapril, Telmisartan, Obesity, Nebivolol, Fosinopril, Eprosartan, Bosentan, Perindopril, Editors, Health
Abstract

2020 FEB 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent by the inventors Iversen, Patrick L. (Corvallis, OR); Annalora, Andrew [...]

Published
2020

12. Findings in the Area of Central Serous Chorioretinopathy Reported from New Cross Hospital (Oral medications for central serous chorioretinopathy: a literature review)

Subjects
Physical fitness, Eplerenone, Eye diseases, Oral drugs, Obesity, Epithelium, Health facilities, Medical research, Editors, Health
Abstract

2019 OCT 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Eye Diseases and Conditions - Central Serous Chorioretinopathy [...]

Published
2019

13. Researchers from Capital Medical University Report Findings in Obesity (Aldosterone Is Involved In the Pathogenesis of Obesity-related Glomerulopathy Through Activation of Wnt/-catenin Signaling In Podocytes)

Subjects
Aldosterone -- Research, Electron microscopes -- Usage, Obesity -- Research, Eplerenone, Glucocorticoids, Physical fitness, Proteinuria, Electron microscopy, Steroids (Organic compounds), Editors, Medical research, Health
Abstract

2019 MAY 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Nutritional and Metabolic Diseases and Conditions - Obesity [...]

Published
2019

14. Investigators at Xinjiang Medical University Describe Findings in Physiology (Eplerenone Reverses Cardiac Fibrosis Via the Suppression of Tregs By Inhibition of Kv1.3 Channel)

Subjects
Cell proliferation -- Research, Heart failure -- Research -- Development and progression, Physiology -- Research, Obesity, Eplerenone, Lymphocytes, Physical fitness, Bone morphogenetic proteins, Transforming growth factors, Fibrosis, Editors, Health
Abstract

2019 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Life Science Research - Physiology. According to [...]

Published
2019

16. Novel drug slows progression of diabetic kidney disease

Author

Zoler, Mitchel L.

Subjects
Canagliflozin, Eplerenone, Type 2 diabetes -- Development and progression, Kidney diseases -- Development and progression, Spironolactone, Health, Health care industry
Abstract

For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists. led to significant reductions in combined adverse renal outcomes and in [...]

Published
2020

18. >Tolsura

Subjects
Lomitapide, Alfuzosin, Ciclesonide, Idelalisib, Daclatasvir, Dienogest, Lurasidone, Solifenacin, Mycoses -- Drug therapy, Dutasteride, Rifabutin, Nisoldipine, Avanafil, Sufentanil, Aprepitant, Rivaroxaban, Apixaban, Darifenacin, Ivacaftor, Cabergoline, Cilostazol, Eletriptan, Simeprevir, Ticagrelor, Vardenafil, Saxagliptin, Bedaquiline, Cinacalcet, Praziquantel, Alfentanil, Itraconazole, Alitretinoin, Tolvaptan, Naloxegol, Fesoterodine, Silodosin, Eliglustat, Ivabradine, Vorapaxar, Anti-HIV agents, Antiarrhythmia agents, Antihypertensive agents, Antineoplastic agents, Histoplasmosis, Dofetilide, Pharmaceutical industry, Respiratory system agents, Antiparasitic agents, Onychomycosis, Phytosterols, Regorafenib, Aliskiren, Fungi, Efavirenz, Cobicistat, Eplerenone, Antifungal agents, Elvitegravir, Aspergillosis, Bosentan, Temsirolimus, Amphotericin B, Pharmacology, Dronedarone, Everolimus, Maraviroc, Blastomycosis, Cell membranes, Plant lipids, Steroids (Organic compounds), Health
Abstract

Company: Mayne Pharma US Rx Pharmacologic class: Azole antifungal Active ingredients: Itraconazole 65mg; caps. Indication: Blastomycosis. Histoplasmosis. Aspergillosis in patients who are intolerant of or refractory to amphotericin B. Limitations [...]

Published
2019

19. [REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].

Author

Overbeck P

Subjects
Double-Blind Method, Early Medical Intervention, Eplerenone, Germany, Heart Failure mortality, Humans, Multicenter Studies as Topic, Myocardial Infarction mortality, Prognosis, Randomized Controlled Trials as Topic, Spironolactone therapeutic use, Survival Rate, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Myocardial Infarction drug therapy, Spironolactone analogs & derivatives
Published
2013
Full Text
View/download PDF

20. [Aldosterone blocker in heart failure: life prolonging even in mild symptoms].

Subjects
Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Early Termination of Clinical Trials, Eplerenone, Germany, Humans, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Spironolactone therapeutic use, Survival Rate, United States, Heart Failure drug therapy, Heart Failure mortality, Mineralocorticoid Receptor Antagonists therapeutic use, Spironolactone analogs & derivatives
Published
2010

21. [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].

Subjects
Drug Administration Schedule, Eplerenone, Heart Failure diagnosis, Humans, Myocardial Infarction diagnosis, Myocardial Infarction drug therapy, Prognosis, Spironolactone therapeutic use, Ventricular Remodeling drug effects, Emergencies, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Myocardial Infarction complications, Spironolactone analogs & derivatives
Published
2008

22. Eplerenone reduces morbidity and mortality after acute MI.

Subjects
Acute Disease, Double-Blind Method, Eplerenone, Erectile Dysfunction chemically induced, Female, Gynecomastia chemically induced, Heart Failure drug therapy, Heart Failure etiology, Heart Failure mortality, Hospitalization, Humans, Hyperkalemia chemically induced, Male, Mineralocorticoid Receptor Antagonists adverse effects, Myocardial Infarction complications, Spironolactone administration & dosage, Spironolactone adverse effects, Ventricular Dysfunction, Left drug therapy, Ventricular Dysfunction, Left mortality, Mineralocorticoid Receptor Antagonists administration & dosage, Myocardial Infarction drug therapy, Myocardial Infarction mortality, Spironolactone analogs & derivatives
Published
2006

23. Pfizer launches Inspra for heart failure.

Subjects
Eplerenone, Heart Failure etiology, Humans, Mineralocorticoid Receptor Antagonists adverse effects, Myocardial Infarction complications, Myocardial Infarction drug therapy, Receptors, Mineralocorticoid drug effects, Spironolactone adverse effects, Spironolactone therapeutic use, Ventricular Dysfunction, Left complications, Ventricular Dysfunction, Left drug therapy, Drug Industry, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Spironolactone analogs & derivatives
Published
2006

24. [Heart failure after myocardial infarction. Increased risk, poorer treatment].

Subjects
Clinical Trials as Topic, Drug Therapy, Combination, Eplerenone, Heart Failure mortality, Hospital Mortality, Humans, Myocardial Infarction mortality, Spironolactone therapeutic use, Survival Rate, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Myocardial Infarction drug therapy, Spironolactone analogs & derivatives
Published
2005

25. [Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required].

Subjects
Angiotensin-Converting Enzyme Inhibitors adverse effects, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Clinical Trials as Topic, Drug Therapy, Combination, Eplerenone, Germany, Humans, Mineralocorticoid Receptor Antagonists adverse effects, Myocardial Infarction mortality, Prognosis, Spironolactone adverse effects, Spironolactone therapeutic use, Survival Rate, Mineralocorticoid Receptor Antagonists therapeutic use, Myocardial Infarction drug therapy, Spironolactone analogs & derivatives
Published
2005

26. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].

Subjects
Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Eplerenone, Heart Failure classification, Heart Failure etiology, Humans, Myocardial Infarction classification, Myocardial Infarction drug therapy, Prognosis, Spironolactone analogs & derivatives, Spironolactone therapeutic use, Ventricular Dysfunction, Left classification, Ventricular Dysfunction, Left etiology, Heart Failure drug therapy, Mineralocorticoid Receptor Antagonists therapeutic use, Myocardial Infarction complications, Ventricular Dysfunction, Left drug therapy
Published
2005

27. [Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].

Subjects
Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Eplerenone, Heart Failure drug therapy, Humans, Myocardial Infarction drug therapy, Myocardial Infarction physiopathology, Neurotransmitter Agents adverse effects, Prognosis, Spironolactone analogs & derivatives, Spironolactone therapeutic use, Stroke Volume drug effects, Stroke Volume physiology, Ventricular Dysfunction, Left drug therapy, Heart Failure physiopathology, Myocardial Infarction complications, Neurotransmitter Agents antagonists & inhibitors, Ventricular Dysfunction, Left physiopathology
Published
2005

28. Two better than one.

Author

SoRelle R

Subjects
Adult, Aged, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Animals, Class Ib Phosphatidylinositol 3-Kinase, Contraindications, Drug Therapy, Combination, Enalapril administration & dosage, Eplerenone, Heart Failure etiology, Humans, Hypertension complications, Hypertrophy, Left Ventricular physiopathology, Isoenzymes deficiency, Isoenzymes physiology, Mice, Mice, Knockout, Middle Aged, Mineralocorticoid Receptor Antagonists administration & dosage, Myocardial Infarction drug therapy, Myocardial Infarction mortality, Myocardial Infarction surgery, Myocardial Reperfusion, Phosphatidylinositol 3-Kinases deficiency, Phosphatidylinositol 3-Kinases physiology, Receptors, Adrenergic, beta metabolism, Spironolactone administration & dosage, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Cognition Disorders etiology, Enalapril therapeutic use, Fibrinolytic Agents, Heart Failure enzymology, Hypertension psychology, Hypertrophy, Left Ventricular drug therapy, Isoenzymes antagonists & inhibitors, Mineralocorticoid Receptor Antagonists therapeutic use, Phosphoinositide-3 Kinase Inhibitors, Spironolactone analogs & derivatives, Spironolactone therapeutic use
Published
2003
Full Text
View/download PDF

29. [Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].

Author

Trifonov IR

Subjects
Acute Disease, Diabetes Complications, Drug Administration Schedule, Drug Therapy, Combination, Eplerenone, Heart Failure etiology, Heart Failure prevention & control, Humans, Mineralocorticoid Receptor Antagonists adverse effects, Myocardial Infarction mortality, Spironolactone adverse effects, Treatment Outcome, Mineralocorticoid Receptor Antagonists administration & dosage, Myocardial Infarction complications, Myocardial Infarction drug therapy, Spironolactone administration & dosage, Spironolactone analogs & derivatives
Published
2003

Catalog

Books, media, physical & digital resources
See catalog results